Synta Pharmaceuticals Corp. Stock Nasdaq
Equities
US87162T2069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 75.33M | Sales 2025 * | 361M | Capitalization | 4.37B |
---|---|---|---|---|---|
Net income 2024 * | -578M | Net income 2025 * | -389M | EV / Sales 2024 * | 48.9 x |
Net cash position 2024 * | 694M | Net cash position 2025 * | 292M | EV / Sales 2025 * | 11.3 x |
P/E ratio 2024 * |
-7.24
x | P/E ratio 2025 * |
-11.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.94% |
Latest transcript on Synta Pharmaceuticals Corp.
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 11-08-31 |
William Sibold
CEO | Chief Executive Officer | - | 23-09-07 |
Rebecca Taub
FOU | Founder | 71 | 16-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 11-08-31 | |
Julian Baker
CHM | Chairman | 57 | 23-06-14 |
Ken Bate
BRD | Director/Board Member | 73 | 16-07-21 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |